IN BRIEF: Indivior faces FDA delay on Sublocade label change

Indivior PLC - Richmond, Virginia-based maker of medicines to treat substance use disorders - ...

Alliance News 12 February, 2025 | 9:18AM
Email Form Facebook Twitter LinkedIn RSS

Indivior PLC - Richmond, Virginia-based maker of medicines to treat substance use disorders - Says it is facing a delay in a review of label changes to Sublocade by the US Food & Drug Administration. The proposed label has been accepted but the final review has been delayed. Sublocade is a treatment for addiction to opioid drugs. Prior to the announcement, the company's share price was down 20% in February.

Current stock price: 822.50 pence, up 7.5%

12-month change: down 41%

By Michael Hennessey, Alliance News reporter

Comments and questions to newsroom@alliancenews.com

Copyright 2025 Alliance News Ltd. All Rights Reserved.

Email Form Facebook Twitter LinkedIn RSS

Securities Mentioned in Article

Security Name Price Change (%) Morningstar
Rating
Indivior PLC Ordinary Share 825.00 GBX 7.84 -

About Author

Alliance News

Alliance News provides Morningstar with continuously updating coverage of news affecting listed companies.

© Copyright 2025 Morningstar, Inc. All rights reserved.

Terms of Use        Privacy Policy        Modern Slavery Statement        Cookie Settings        Disclosures